Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic changes upon doxorubicin treatment in hCMEC/D3

ABSTRACT: Current chemotherapy regimens have significantly improved overall survival for children with cancer. However, these curative treatments are associated with detrimental side effects such as chemotherapy-induced cognitive impairment (CICI), or “chemobrain.” Measurable deficits in cognitive function may persist years after chemotherapy treatments, significantly reducing quality of life. Specifically, doxorubicin (DOXO), a commonly used chemotherapeutic agent in curative regimens for children with cancer, plays a pivotal role in the development of CICI, even though it does not cross the blood brain barrier (BBB). We propose to address the poorly understood mechanism of DOXO-related CICI by studying changes induced by DOXO in BBB integrity in vitro, using human cerebral microvascular endothelial cells (hCMEC/D3). Our findings provide critical insights on how DOXO impacts the BBB and builds a foundation for developing preventative measures and therapeutic interventions that may improve the quality of life for patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE305805 | GEO | 2025/11/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic changes upon doxorubicin treatment in the brain of ApoE3 and ApoE4 rats

Project description:Many pediatric cancer survivors experience chemotherapy-induced cognitive impairment (CICI), which negatively impacts the quality of life and the interpatient variability in susceptibility to CICI is not well understood. Among pediatric cancer survivors, those with the E4 allele of Apolipoprotein E (ApoE) are more likely to exhibit cognitive dysfunction than those with the more prevalent ApoE3 allele, suggesting the ApoE4 allele increases susceptibility to CICI. To mimic a curative pediatric treatment regimen, in our experimental model, five-week-old rats homozygous for either human ApoE3 or ApoE4 allele were treated with doxorubicin (2mg/kg/week for 4 weeks) or PBS (saline). This study aims to investigate transcriptomic changes in different regions of brain to determine the impact of doxorubicin treatment in ApoE3 and ApoE4 rats.

2025-12-22 | GSE305230 | GEO

Nicotinamide Mononucleotide administration prevents doxorubicin-induced cardiotoxicity and loss in physical activity in mice.

Project description:In this study we investigated whether nicotinamide mononucleotide (NMN) could protect against Doxorubicin-induced cardiotoxicity and physical dysfunction in vivo. To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic. In the acute study, C57BL6/J (B6) mice were injected intraperitoneally (i.p.) once with Doxo (20 mg/kg) and NMN (180 mg/kg/day, i.p.) was administered daily for five days before and after the Doxo injection. In the chronic study, B6 mice received a cumulative dose of 20 mg/kg Doxo administered in fractionated doses for five days. NMN (500 mg/kg/day) was supplied in the mice’s drinking water beginning five days before the first injection of Doxo and continuing for 60 days after.

2023-01-11 | GSE221003 | GEO

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer

Project description:Matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) data investigating changes in extracellular matrix/collagen architecture of mouse tumor tissue in response to LOX inhibition. Sample Key: Vehicle, Doxo (Chemotherapy drug), 6403 (LOX inhibitor), Combo (Doxo + LOX inhibitor)

2024-07-25 | PXD052657 | Pride

Doxorubicin treatment effects on the young mouse brain transcriptome

Project description:Doxorubicin (Doxo) is a common chemotherapeutic reagent associated with mitochondrial dysfunction, DNA damage, and cognitive impairment in human cancer patients. The purpose of this study was to determine the transcriptional effects of Doxo on the brains of young mice. 4 month old C57B6/J male mice were injected with saline sham or 10mg/kg Doxo +/- MitoQ (a mitochondria-specific antioxidant). Hippocampi were harvested from these mice and RNA was isolated to perform polyA RNA-seq to profile gene expression.

2021-06-25 | GSE178812 | GEO

Changes in Gut, Microbiome, and Cognition after Doxorubicin, Cyclophosphamide, and Paclitaxel Chemotherapy Treatment

Project description:Chemotherapy induced cognitive impairment (CICI), or “chemobrain”, is defined as an impairment in memory, learning, executive function, and attention following chemotherapy treatment. In this study, 12-week-old female C57/BL6 mice were treated with 8 once weekly intraperitoneal injections (IP) of the following chemotherapeutic treatment groups: 1) Doxorubicin (Dox), Cyclophosphamide (CYP), and Paclitaxel (PTX) (AC-T) or 2) saline. At 30 days after the last AC-T or Saline injection, mice underwent the three-chamber sociability test to assess social behavior and social memory. AC-T treated mice spent equal time with both the novel and the stranger mouse, indicating a deficit in social memory. RNA sequencing showed changes in networks associated with neurogenesis, axonal guidance and neurotransmission.

2025-05-29 | GSE295281 | GEO

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [RNA-Seq]

Project description:H3.3G34R/V hemispheric gliomas carrya dismal prognosisas current treatments including radio/chemotherapy are not curative. We undertook a systematic and comprehensive epigenetic approach to define therapeutic dependenciesin H3.3G34R/V gliomas.

2021-12-15 | GSE161288 | GEO

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [ChIP-Seq]

Project description:H3.3G34R/V hemispheric gliomas carry a dismal prognosis as current treatments including radio/chemotherapy are not curative. We undertook a systematic and comprehensive epigenetic approach to define therapeutic dependencies in H3.3G34R/V gliomas.

2021-12-15 | GSE161287 | GEO

Transcriptomic analysis of hCMEC/D3 cells after SiNPs treatment

Project description:hCMEC/D3 cells were treated with SiNPs for 24 h. It was discovered that SiNP_35 nm and SiNP_58 nm were both penetrated through the BBB via caveolin-mediated pathway, and both sizes induced the upregulation of the inflammation pathways.

2022-06-14 | GSE205739 | GEO

Machine learning-assisted classification of responders and non-responders to bortezomib treatment regimens PAD and VCD using new experimental dataset of 58 multiple myeloma RNA sequencing profiles

Project description:Multiple myeloma (MM) is a hematological cancer which arises from abnormal antibody producing white blood plasma cells. MM affected approximately 500 000 people and results in ~100 000 deaths annually, being currently considered treatable but uncurable. There are several MM chemotherapy treatment regimens, among which ten include bortezomib, a proteasome-targeted drug. Patients with MM respond differently on bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated molecular profiles of MM that could be used to establish novel molecular diagnostics. In this study we report new molecular profiles for 58 MM patients annotated with data on two chemotherapy regimens which include bortezomib, doxorubicin, and dexamethasone (PAD) or bortezomib, cyclophosphamide, and dexamethasone (VCD). MM biosamples were taken prior to first line chemotherapy treatments and subjected to RNA sequencing.

2021-10-01 | GSE159426 | GEO

RNA-seq of human brain endothelial cells treated with Nrf2 activator RTA-404

Project description:Systemic inflammation can lead to a compromised blood-brain barrier (BBB) and neuro-inflammation, with acute consequences such as delirium, and long-lasting deleterious effects including cognitive decline and the exacerbation of neurodegenerative disease progression. Previous studies have shown beneficial roles of Nrf2 in the development and homeostastis of endothelial cells, an integral component of the BBB. We performed RNA-seq on human brain endothelial cells, in a control condition and treated with RTA-404 (CDDO-TFEA), a potent stimulator of Nrf2.

2025-03-27 | E-MTAB-14978 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data